{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:11:37Z","timestamp":1787991097718,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12072-023-10528-7","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:02:52Z","timestamp":1682521372000},"page":"860-869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Eui Gwon","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-0381","authenticated-orcid":false,"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"10528_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12072-007-9006-5","volume":"1","author":"G Lau","year":"2007","unstructured":"Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int. 2007;1:316\u2013325","journal-title":"Hepatol Int"},{"key":"10528_CR2","doi-asserted-by":"publisher","first-page":"20160274","DOI":"10.1098\/rstb.2016.0274","volume":"372","author":"M Ringelhan","year":"2017","unstructured":"Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160274","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10528_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"Collaborators GBDHB","year":"2022","unstructured":"Collaborators GBDHB. Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7:796\u2013829","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10528_CR4","unstructured":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J Korean Liver Cancer Stud Group 2022;0."},{"key":"10528_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17998\/jlc.2022.03.18","volume":"22","author":"SL Renne","year":"2022","unstructured":"Renne SL, Tommaso LD. A clinical and pathological update on hepatocellular carcinoma. J Liver Cancer. 2022;22:14\u201322","journal-title":"J Liver Cancer"},{"key":"10528_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3350\/cmh.2022.0084","volume":"28","author":"Korean Association for the Study of the L","year":"2022","unstructured":"Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2022;28:276\u2013331","journal-title":"Clin Mol Hepatol."},{"key":"10528_CR7","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.4254\/wjh.v7.i18.2127","volume":"7","author":"LC Meireles","year":"2015","unstructured":"Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7:2127\u20132132","journal-title":"World J Hepatol"},{"key":"10528_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/apt.15867","volume":"52","author":"H Oh","year":"2020","unstructured":"Oh H, Jun DW, Lee IH, Ahn HJ, Kim BO, Jung S, et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:371\u2013381","journal-title":"Aliment Pharmacol Ther"},{"key":"10528_CR9","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10528_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jgh3.12481","volume":"5","author":"BT Lee","year":"2021","unstructured":"Lee BT, Chang M, Lim C, Bae HS, Fong TL. Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients. JGH Open. 2021;5:258\u2013263","journal-title":"JGH Open"},{"key":"10528_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1570162X18666200824101838","volume":"19","author":"J Lagoutte-Renosi","year":"2021","unstructured":"Lagoutte-Renosi J, Flammang M, Chirouze C, Beck-Wirth G, Bozon F, Brunel AS, et al. Real-life impact on lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected patients. Curr HIV Res. 2021;19:84\u201389","journal-title":"Curr HIV Res"},{"key":"10528_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1186\/s12879-021-06479-9","volume":"21","author":"PE Plum","year":"2021","unstructured":"Plum PE, Maes N, Sauvage AS, Frippiat F, Meuris C, Uurlings F, et al. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis. 2021;21:910","journal-title":"BMC Infect Dis"},{"key":"10528_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10528_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3350\/cmh.2021.0314","volume":"28","author":"J Jeong","year":"2022","unstructured":"Jeong J, Shin JW, Jung SW, Park EJ, Park NH. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis. Clin Mol Hepatol. 2022;28:254\u2013264","journal-title":"Clin Mol Hepatol"},{"key":"10528_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408\u2013414","journal-title":"J Clin Epidemiol"},{"key":"10528_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/2050640617751252","volume":"6","author":"S Cai","year":"2018","unstructured":"Cai S, Ou Z, Liu D, Liu L, Liu Y, Wu X, et al. Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome. United European Gastroenterol J. 2018;6:558\u2013566","journal-title":"United European Gastroenterol J"},{"key":"10528_CR17","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/cancers13071599","volume":"13","author":"Y Cho","year":"2021","unstructured":"Cho Y, Cho EJ, Yoo JJ, Chang Y, Chung GE, Jeong SM, et al. Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers (Basel). 2021;13:1599","journal-title":"Cancers (Basel)"},{"key":"10528_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005146","volume":"95","author":"H Wang","year":"2016","unstructured":"Wang H, Lu X, Yang X, Xu N. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016;95: e5146","journal-title":"Medicine (Baltimore)"},{"key":"10528_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","volume":"34","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, et al. Tenofovir alafenamide vs tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34:2259\u20132268","journal-title":"AIDS"},{"key":"10528_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bcpt.13161","volume":"124","author":"P Cid-Silva","year":"2019","unstructured":"Cid-Silva P, Fernandez-Bargiela N, Margusino-Framinan L, Balboa-Barreiro V, Mena-De-Cea A, Lopez-Calvo S, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124:479\u2013490","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10528_CR21","doi-asserted-by":"publisher","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","volume":"9","author":"PWG Mallon","year":"2022","unstructured":"Mallon PWG, Brunet L, Fusco JS, Prajapati G, Beyer A, Fusco GP, et al. Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides. Open Forum Infect Dis. 2022;9:ofab621","journal-title":"Open Forum Infect Dis"},{"key":"10528_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261760","volume":"17","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS ONE. 2022;17: e0261760","journal-title":"PLoS ONE"},{"key":"10528_CR23","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40261-021-01081-y","volume":"41","author":"L Brunet","year":"2021","unstructured":"Brunet L, Mallon P, Fusco JS, Wohlfeiler MB, Prajapati G, Beyer A, et al. Switch from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: lipid changes and statin underutilization. Clin Drug Investig. 2021;41:955\u2013965","journal-title":"Clin Drug Investig"},{"key":"10528_CR24","doi-asserted-by":"publisher","first-page":"135965352210823","DOI":"10.1177\/13596535221082399","volume":"27","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li Z, Luo Q, Xu W, Wang L, Zhu S, et al. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study. Antivir Ther. 2022;27:13596535221082400","journal-title":"Antivir Ther"},{"key":"10528_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3350\/cmh.2022.0028","volume":"28","author":"HY Lin","year":"2022","unstructured":"Lin HY, Tseng TC. Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: facts and puzzles. Clin Mol Hepatol. 2022;28:181\u2013182","journal-title":"Clin Mol Hepatol"},{"key":"10528_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/apt.14218","volume":"46","author":"AA Shaheen","year":"2017","unstructured":"Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46:599\u2013604","journal-title":"Aliment Pharmacol Ther"},{"key":"10528_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24: e25702","journal-title":"J Int AIDS Soc"},{"key":"10528_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijid.2019.12.029","volume":"92","author":"PH Kuo","year":"2020","unstructured":"Kuo PH, Sun HY, Chuang YC, Wu PY, Liu WC, Hung CC. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide. Int J Infect Dis. 2020;92:71\u201377","journal-title":"Int J Infect Dis"},{"key":"10528_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441\u2013453","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10528_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","volume":"16","author":"A Mills","year":"2016","unstructured":"Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43\u201352","journal-title":"Lancet Infect Dis"},{"key":"10528_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00535-020-01750-3","volume":"56","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168\u2013180","journal-title":"J Gastroenterol"},{"key":"10528_CR32","doi-asserted-by":"publisher","first-page":"re3","DOI":"10.1126\/scisignal.272re3","volume":"2","author":"RL Silverstein","year":"2009","unstructured":"Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:re3","journal-title":"Sci Signal"},{"key":"10528_CR33","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.2337\/db07-0907","volume":"56","author":"DP Koonen","year":"2007","unstructured":"Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;56:2863\u20132871","journal-title":"Diabetes"},{"key":"10528_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/ATVBAHA.107.161653","volume":"28","author":"V Luangrath","year":"2008","unstructured":"Luangrath V, Brodeur MR, Rhainds D, Brissette L. Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo. Arterioscler Thromb Vasc Biol. 2008;28:1290\u20131295","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10528_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.M011981","volume":"52","author":"M Brundert","year":"2011","unstructured":"Brundert M, Heeren J, Merkel M, Carambia A, Herkel J, Groitl P, et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res. 2011;52:745\u2013758","journal-title":"J Lipid Res"},{"key":"10528_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/QAD.0000000000002541","volume":"34","author":"A Lacey","year":"2020","unstructured":"Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, et al. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020;34:1161\u20131170","journal-title":"AIDS"},{"key":"10528_CR37","doi-asserted-by":"publisher","first-page":"59666","DOI":"10.18632\/oncotarget.19611","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang Y, Xiong J, Niu M, Chen X, Gao L, Wu Q, et al. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget. 2017;8:59666\u201359676","journal-title":"Oncotarget"},{"key":"10528_CR38","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.30973","volume":"71","author":"MJ Goh","year":"2020","unstructured":"Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology. 2020;71:2023\u20132032","journal-title":"Hepatology"},{"key":"10528_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12876-020-01222-1","volume":"20","author":"X Li","year":"2020","unstructured":"Li X, Sheng L, Liu L, Hu Y, Chen Y, Lou L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol. 2020;20:98","journal-title":"BMC Gastroenterol"},{"key":"10528_CR40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/pharmacy10060164","volume":"10","author":"JM Gilbert","year":"2022","unstructured":"Gilbert JM, Vest K, Kish TD. Long-term evaluation of changes in kidney function after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients living with HIV. Pharmacy (Basel). 2022;10:164","journal-title":"Pharmacy (Basel)"},{"key":"10528_CR41","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.bbadis.2008.09.004","volume":"1792","author":"E van den Berg","year":"2009","unstructured":"van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta. 2009;1792:470\u2013481","journal-title":"Biochim Biophys Acta"},{"key":"10528_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1758-5996-2-55","volume":"2","author":"A Halpern","year":"2010","unstructured":"Halpern A, Mancini MC, Magalhaes ME, Fisberg M, Radominski R, Bertolami MC, et al. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment. Diabetol Metab Syndr. 2010;2:55","journal-title":"Diabetol Metab Syndr"},{"key":"10528_CR43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u2013195","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10528_CR44","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/liv.15261","volume":"42","author":"J Lim","year":"2022","unstructured":"Lim J, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na\u00efve chronic hepatitis B. Liver Int. 2022;42:1517\u20131527","journal-title":"Liver Int"},{"key":"10528_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","volume":"21","author":"J Li","year":"2021","unstructured":"Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis. 2021;21:567","journal-title":"BMC Infect Dis"},{"key":"10528_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/hepr.13726","volume":"52","author":"T Hosaka","year":"2022","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, et al. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res. 2022;52:153\u2013164","journal-title":"Hepatol Res"},{"key":"10528_CR47","volume":"21","author":"I Akdemir Kalkan","year":"2021","unstructured":"Akdemir Kalkan I, Karasahin O, Sarigul F, Altunisik Toplu S, Aladag M, Akgul F, et al. Comparison of tenofovir alafenamide and entecavir therapy in patients with chronic hepatitis B initially treated with tenofovir disoproxil. Retrosp Obs Surv. 2021;21: e118721","journal-title":"Retrosp Obs Surv"},{"key":"10528_CR48","first-page":"1","volume":"21","author":"O Karasahin","year":"2021","unstructured":"Karasahin O, Kalkan IA, Dal T, Toplu SA, Harputo\u011flu M, Mete AO, et al. Real-life data for tenofovir alafenamide fumarate treatment of hepatitis B: the pythagoras cohort. Hepat Mon. 2021;21:1\u20139","journal-title":"Hepat Mon"},{"key":"10528_CR49","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/apt.17107","volume":"56","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, et al. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther. 2022;56:713\u2013722","journal-title":"Aliment Pharmacol Ther"},{"key":"10528_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000519440","volume":"65","author":"S Jeong","year":"2022","unstructured":"Jeong S, Shin HP, Kim HI. Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B. Intervirology. 2022;65:94\u2013103","journal-title":"Intervirology"},{"key":"10528_CR51","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","volume":"20","author":"KS Byun","year":"2022","unstructured":"Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, et al. Tenofovir alafenamide for drug-resistant hepatitis B: A randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20:427-437.e425","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10528_CR52","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u2013681","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10528-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10528-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10528-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T07:12:40Z","timestamp":1709363560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10528-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10528"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10528-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"2 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (Eui Gwon Hwang, Eun-Ae Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim) have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was waived from the Institutional Review Board and our study conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}